Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study aims to unlock secrets of COPD attacks

NCT ID NCT05008081

Knowledge-focused Sponsor: Wim Janssens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 1000 adults hospitalized for a sudden worsening of COPD (a lung disease). Researchers will collect medical data and biological samples over time to better understand these flare-ups. The goal is to improve future prevention and treatment, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide insights that lead to better treatments or management strategies for COPD exacerbations.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly benefit participants. Results may take years to influence care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with COPD, hospitalized for an acute exacerbation

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years and older * Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test with an FEV1/FVC \< 0.7) * Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD) * Inclusion within 48 hours post hospital admission * Voluntary written informed consent of the participant or his/her representative obtained prior to any study procedure Exclusion Criteria: * Patients unwilling or unable to comply with study procedures * Patients not requiring treatment with systemic corticosteroids, antibiotics or both as a minimum therapy for the index AECOPD * Patients with a confirmed positive test result for COVID19, or those highly suspected based on clinical examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute exacerbation of chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease exacerbation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites in 11 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU St-Pierre Brussels

    RECRUITING

    Brussels, 1000, Belgium

  • CHU UCL Namur Site Godinne

    RECRUITING

    Yvoir, 5530, Belgium

  • CHU de Lille

    NOT_YET_RECRUITING

    Lille, 59000, France

  • Churchil Hospital

    NOT_YET_RECRUITING

    Oxford, United Kingdom

  • Cochin Hospital

    NOT_YET_RECRUITING

    Paris, France

  • Gazi University Hospital

    RECRUITING

    Ankara, 06560, Turkey (Türkiye)

  • Glenfield Hospital

    RECRUITING

    Leicester, United Kingdom

  • Guy's Saint Thomas

    NOT_YET_RECRUITING

    London, United Kingdom

  • Hospital Clinic de Barcelona

    NOT_YET_RECRUITING

    Barcelona, Spain

  • Kepler University Hospital

    RECRUITING

    Linz, Austria

  • Klinikum Itzehoe

    RECRUITING

    Itzehoe, 25524, Germany

  • LungenClinic

    RECRUITING

    Großhansdorf, Germany

  • Maastricht University Medical Hospital

    NOT_YET_RECRUITING

    Maastricht, Netherlands

  • Royal Brompton Hospital

    ACTIVE_NOT_RECRUITING

    London, United Kingdom

  • Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, Sweden

  • UMC Groningen

    NOT_YET_RECRUITING

    Groningen, 9713, Netherlands

  • UZ Leuven

    RECRUITING

    Leuven, 3000, Belgium

  • University Hospital

    NOT_YET_RECRUITING

    Golnik, Slovenia

  • University Hospital Schleswig-Holstein

    NOT_YET_RECRUITING

    Kiel, Germany

  • University Hospital Vienna

    NOT_YET_RECRUITING

    Vienna, Austria

  • University Hospital of Ferrara

    NOT_YET_RECRUITING

    Ferrara, Italy

  • University Medical Centre of Gießen & Marburg

    RECRUITING

    Marburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.